- Ipsen’s first-quarter sales exceeded expectations, reaching EU918.8 million compared to an estimate of EU908.3 million.
- The company’s oncology revenue came in strong at EU655.0 million, surpassing the anticipated EU646.2 million.
- Neuroscience revenue also outperformed predictions, achieving EU193.5 million versus the estimated EU190.9 million.
- Revenue from rare diseases fell slightly short of expectations at EU70.3 million, against an estimate of EU72.2 million.
- Analyst recommendations for Ipsen include 8 buys, 8 holds, and 2 sells.
“`
A look at Ipsen SA Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Investors looking at Ipsen SA‘s long-term outlook may find a mixed bag of scores according to the Smartkarma Smart Scores. With a Value score of 3, Ipsen SA seems to be reasonably priced in the market. The company’s Growth score of 3 indicates a moderate level of growth potential ahead. In terms of Dividend, Ipsen SA scores a 2, suggesting a lower emphasis on dividend payouts. However, the company’s high Resilience score of 4 highlights its ability to weather economic uncertainties. Momentum, with a score of 3, shows a steady pace of development for Ipsen SA.
Ipsen SA, a manufacturer and marketer of medical drugs targeting oncology, endocrinology, and neuromuscular disorders, presents a balanced outlook based on the Smartkarma Smart Scores. While the company scores higher in terms of Resilience, indicating its strength during challenging times, areas like Dividend and Growth show room for improvement. Investors may view Ipsen SA as a stable player in the healthcare sector with a promising future given its varied focus on crucial disease areas.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
